/
ADCT
$1.03+$0.01 (+0.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$129.7M
127M shares
52-week range
$0.78 – $4.98
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
2.09%
Moderate
Price (6 mo)
Loading chart…
Change$-23.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $2.3M | $0 | $33.9M | $209.9M | $69.6M | $70.8M | $81.4M |
| Cost of revenue | $118.1M | $0 | $141.8M | $1.4M | $3.3M | $2.5M | $5.9M | $7.7M |
| Gross profit | −$116.9M | $2.3M | −$141.8M | $32.5M | $206.6M | $67.0M | $64.9M | $73.7M |
| Gross margin | -10258.4% | 100.0% | — | 95.9% | 98.4% | 96.4% | 91.6% | 90.6% |
| R&D | $118.3M | $107.5M | $142.0M | $158.0M | $186.5M | $127.1M | $109.6M | $104.0M |
| Operating income | −$125.9M | −$119.4M | −$219.3M | −$261.7M | −$123.3M | −$166.0M | −$130.7M | −$108.4M |
| EBITDA | −$122.4M | −$114.1M | −$218.2M | −$230.5M | −$107.7M | −$145.8M | −$102.6M | −$89.3M |
| Net income | −$123.1M | −$116.5M | −$246.3M | −$230.0M | −$157.1M | −$240.1M | −$157.8M | −$142.6M |
| Net margin | -10797.9% | -4977.9% | — | -678.2% | -74.9% | -345.1% | -222.8% | -175.3% |
| EPS (diluted) | -2.29 | -1.74 | -3.77 | -3.00 | -1.99 | -2.94 | -1.62 | -1.12 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $81M | $-0.85 | $-0.87–$-0.83 | 4 |
| 2027 | $115M | $-0.66 | $-0.74–$-0.57 | 4 |
| 2028 | $206M | $-0.27 | $-1.54–$1.22 | 4 |
| 2029 | $304M | $0.33 | $0.31–$0.37 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
www.adctherapeutics.com- Employees
- 193
- IPO / List date
- May 15, 2020
- HQ
- EPALINGES, V8
Held by traders on TradeandTell
No one on the platform currently holds ADCT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ADCT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2005-05-10 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded ADCT yet.
